{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:32:33Z","timestamp":1789651953308,"version":"4.0.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-988-6569"],"award-info":[{"award-number":["IN-US-988-6569"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jhepr.2023.100852","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T04:18:30Z","timestamp":1689740310000},"page":"100852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B"],"prefix":"10.1016","volume":"5","author":[{"given":"Zeyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit S.","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-2806","authenticated-orcid":false,"given":"Robert J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100852_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/hep.31782","article-title":"An updated\u00a0assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States","volume":"74","author":"Wong","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100852_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000001530","article-title":"Low rates of hepatitis B virus treatment among treatment-eligible patients in safety-net health systems","volume":"56","author":"Wong","year":"2022","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100852_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1844","article-title":"Diagnosis rates of chronic hepatitis B in privately insured patients in the United States","volume":"3","author":"Ogawa","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2023.100852_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jceh.2017.11.009","article-title":"High prevalence of cirrhosis at initial presentation among safety-net adults with chronic hepatitis B virus infection","volume":"8","author":"Tang","year":"2018","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2023.100852_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.cgh.2018.10.003","article-title":"Low rates of linkage and retention into care among patients with chronic HBV infection","volume":"17","author":"Tang","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100852_bib7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.26286","article-title":"Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010","volume":"58","author":"Hu","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100852_bib9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.14309\/ajg.0000000000001195","article-title":"Antiviral therapy reduces risk of cirrhosis in noncirrhotic HBV patients among 4 urban safety-net health systems","volume":"116","author":"Wong","year":"2021","journal-title":"The Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100852_bib10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/apt.16786","article-title":"Risk of hepatocellular carcinoma in treatment-naive chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States","volume":"55","author":"Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100852_bib12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/jvh.13601","article-title":"Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B","volume":"28","author":"Lee","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100852_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100852_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2023.100852_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100852_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100852_bib17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk\u00a0factors for hepatocellular carcinoma: synergism of alcohol with viral\u00a0hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3350\/cmh.2021.0383","article-title":"Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases","volume":"28","author":"Shin","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100852_bib19","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100852_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/add.16034","article-title":"Using the alcohol use disorders identification test to predict hospital admission for alcohol-related conditions in the Danish general population: a record-linkage study","volume":"118","author":"Brummer","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.jhepr.2023.100852_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.32394","article-title":"Racial\/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018","volume":"76","author":"Alvarez","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/jgh.13473","article-title":"Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: an analysis using time-dependent receiver operating characteristic","volume":"32","author":"Tada","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100852_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/hep.27654","article-title":"High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers","volume":"61","author":"Suh","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2023.100852_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004602","article-title":"Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients","volume":"95","author":"Demir","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jhepr.2023.100852_bib26","article-title":"The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"PloS one"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:07:55Z","timestamp":1778904475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2589555923001830"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100852","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100852"}}